Because HA levels can shape melanoma cell behaviour, these coordinated changes in HAS–Hyal activity suggest a PACAP-driven shift in ECM dynamics rather than a unidirectional pro- or anti-tumour effect. The gene discussed is HAS1; the disease is melanoma.